NO20010525D0 - Lipidsenkende kinazolinderivat - Google Patents
Lipidsenkende kinazolinderivatInfo
- Publication number
- NO20010525D0 NO20010525D0 NO20010525A NO20010525A NO20010525D0 NO 20010525 D0 NO20010525 D0 NO 20010525D0 NO 20010525 A NO20010525 A NO 20010525A NO 20010525 A NO20010525 A NO 20010525A NO 20010525 D0 NO20010525 D0 NO 20010525D0
- Authority
- NO
- Norway
- Prior art keywords
- lowering
- lipid
- quinazoline derivative
- cholesterol
- carbonyl
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- VWYAGHXULKUVQY-UHFFFAOYSA-N (3-bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)methanone Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1C(=O)C1=CC=CC(Br)=C1 VWYAGHXULKUVQY-UHFFFAOYSA-N 0.000 abstract 1
- KHTZEFSHZJPOTJ-UHFFFAOYSA-N 1h-quinazolin-2-ylidenemethanone Chemical class C1=CC=C2C=NC(=C=O)NC2=C1 KHTZEFSHZJPOTJ-UHFFFAOYSA-N 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- -1 carbonyl-substituted quinazoline Chemical class 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/126,940 US6172071B1 (en) | 1998-07-30 | 1998-07-30 | Lipid-lowering quinazoline derivative |
| PCT/US1999/015841 WO2000006554A1 (en) | 1998-07-30 | 1999-07-13 | Lipid-lowering quinazoline derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20010525D0 true NO20010525D0 (no) | 2001-01-30 |
| NO20010525L NO20010525L (no) | 2001-01-30 |
Family
ID=22427479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20010525A NO20010525L (no) | 1998-07-30 | 2001-01-30 | Lipidsenkende kinazolinderivat |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6172071B1 (no) |
| EP (1) | EP1100787B1 (no) |
| JP (1) | JP2002521475A (no) |
| KR (1) | KR20010089146A (no) |
| AT (1) | ATE306476T1 (no) |
| AU (1) | AU750653B2 (no) |
| CA (1) | CA2338825A1 (no) |
| DE (1) | DE69927689T2 (no) |
| HU (1) | HUP0102887A2 (no) |
| IL (1) | IL141025A0 (no) |
| MX (1) | MXPA01001139A (no) |
| NO (1) | NO20010525L (no) |
| WO (1) | WO2000006554A1 (no) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
| US6172071B1 (en) | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| US6410545B2 (en) | 1998-07-30 | 2002-06-25 | Parker Hughes Institute | Lipid lowering quinazoline dietary supplement composition |
| TR200500745T2 (tr) | 1999-02-10 | 2005-05-23 | Astrazeneca Ab | Damar gelişimi inhibitörleri olarak kuinazolin türevleri. |
| US6126917A (en) * | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| BR0307151A (pt) | 2002-02-01 | 2004-12-07 | Astrazeneca Ab | Composto ou um sal do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso do composto ou de um seu sal, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, como um ser humano, que necessita de um tratamento do tipo referido, e, processos para a preparação de 5-bromo-7- azaindol, e para a produção de 5-metóxi-7-azaindol |
| GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| CN101065137A (zh) * | 2004-09-16 | 2007-10-31 | 加利福尼亚大学董事会 | 用于改善动脉粥样硬化和其它病变的g型多肽和其它剂 |
| US7579319B2 (en) | 2004-12-06 | 2009-08-25 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| CN104016929B (zh) * | 2014-06-25 | 2016-03-30 | 北京理工大学 | 一种合成喹唑啉-4(3h)-酮的方法 |
| LT3416684T (lt) * | 2016-02-17 | 2023-07-25 | Regeneron Pharmaceuticals, Inc. | Aterosklerozės gydymo ar prevencijos būdai, skiriant angptl3 inhibitorių |
| AU2017227713B2 (en) | 2016-03-03 | 2022-12-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US6172071B1 (en) | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
-
1998
- 1998-07-30 US US09/126,940 patent/US6172071B1/en not_active Expired - Fee Related
-
1999
- 1999-07-13 AU AU49913/99A patent/AU750653B2/en not_active Ceased
- 1999-07-13 WO PCT/US1999/015841 patent/WO2000006554A1/en not_active Ceased
- 1999-07-13 AT AT99933976T patent/ATE306476T1/de not_active IP Right Cessation
- 1999-07-13 CA CA002338825A patent/CA2338825A1/en not_active Abandoned
- 1999-07-13 KR KR1020017001293A patent/KR20010089146A/ko not_active Withdrawn
- 1999-07-13 MX MXPA01001139A patent/MXPA01001139A/es unknown
- 1999-07-13 EP EP99933976A patent/EP1100787B1/en not_active Expired - Lifetime
- 1999-07-13 HU HU0102887A patent/HUP0102887A2/hu unknown
- 1999-07-13 DE DE69927689T patent/DE69927689T2/de not_active Expired - Fee Related
- 1999-07-13 JP JP2000562357A patent/JP2002521475A/ja active Pending
- 1999-07-13 IL IL14102599A patent/IL141025A0/xx unknown
-
2001
- 2001-01-08 US US09/756,483 patent/US6355645B2/en not_active Expired - Fee Related
- 2001-01-30 NO NO20010525A patent/NO20010525L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102887A2 (hu) | 2003-02-28 |
| EP1100787B1 (en) | 2005-10-12 |
| US6172071B1 (en) | 2001-01-09 |
| WO2000006554A1 (en) | 2000-02-10 |
| MXPA01001139A (es) | 2002-04-24 |
| IL141025A0 (en) | 2002-02-10 |
| EP1100787A1 (en) | 2001-05-23 |
| CA2338825A1 (en) | 2000-02-10 |
| JP2002521475A (ja) | 2002-07-16 |
| NO20010525L (no) | 2001-01-30 |
| US6355645B2 (en) | 2002-03-12 |
| AU4991399A (en) | 2000-02-21 |
| AU750653B2 (en) | 2002-07-25 |
| ATE306476T1 (de) | 2005-10-15 |
| KR20010089146A (ko) | 2001-09-29 |
| DE69927689D1 (de) | 2006-02-23 |
| US20010008894A1 (en) | 2001-07-19 |
| DE69927689T2 (de) | 2006-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20010525D0 (no) | Lipidsenkende kinazolinderivat | |
| WO2002032893A3 (en) | Piperidine compounds as anti-allergic | |
| EP1707563A3 (en) | Methods and compositions utilizing quinazolinones | |
| MY131890A (en) | Piperidine compounds | |
| ATE355278T1 (de) | Isochinolinon derivate als parp inhibitoren | |
| AU2002316459A1 (en) | Methods of treating cytokine mediated diseases | |
| DE69613705D1 (de) | Piperinderivate als neurokininantagoniste | |
| EP1686120A3 (en) | Methods and compositions utilizing quinazolinones | |
| HK1047283A1 (zh) | 以四羥基喹啉葎基(tetrahydroquinolinyl)、芳基或雜芳基和烷基取代的具有視網膜樣的生物活性的胺類 | |
| EP1450808B8 (en) | Quinazoline derivatives for the treatment of t cell mediated diseases | |
| NO20005864L (no) | Kinazoliner til behandling av hjernesvulst | |
| AU2002313249A1 (en) | Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same | |
| ATE496893T1 (de) | Isochinolinonderivate und deren verwendung als medikamente | |
| DE60204349D1 (de) | 4-(1,3,4-thiadiazolyl-2-yl)-1,4-diazabizyklo- 3.2.2 nonanderivate, ihre herstellung und ihre therapeutische verwendung | |
| DE60001451T2 (de) | 1,4-diazabicyclo[3.2.2]nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung | |
| DE60324544D1 (de) | Muskarin antagonisten | |
| CA2330447A1 (en) | N-(3-ethynylphenyl-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate | |
| EP1254662A3 (en) | Methods and kits for treating depression or preventing deterioration of cognitive function | |
| DE60103394D1 (de) | 4-(2-phenylthiazol-5-yl)1,4-diazabicyclo[3.2.2]nonanederivate, ihre herstellung und therapeutische verwendung | |
| ATE375359T1 (de) | Aminosterolderivate und ihre verwendungen | |
| EP1168918A4 (en) | VACCINE AND GENE THERAPY COMPOSITIONS AND METHOD FOR THEIR PRODUCTION AND USE | |
| DK1546119T3 (da) | Fremgangsmåde til fremstilling af 4-(3'chlor-4'-fluoranilin)-7-methoxy-6-(3-morpholinpropoxy) quinazoline | |
| AU2001290480A1 (en) | Cyclized benzamide neurokinin antagonists for use in therapy | |
| MY136297A (en) | Piperazine derivatives having sst1 antagonistic activity | |
| NZ335052A (en) | Piperazino derivatives as neurokinin antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |